International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

LEARN MORE

PreScription: 2014 in Review

Author(s): Allen Loyd V Jr

Issue: Jan/Feb 2015 - Volume 19, Number 1
View All Articles in Issue

Page(s): 4

Download in electronic PDF format for $75

Abstract:

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, Drug Quality and Security Act, Section 503A, U.S. Federal Food, Drug, and Cosmetic Act, pharmacy benefit managers, CompoundingToday.com

Related Categories: LEGAL, QUALITY CONTROL, PROFESSIONAL ISSUES, INFORMATION RESOURCES

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
PreScription: 2014 in Review Allen Loyd V Jr	Jan/Feb 2015 Pg. 4
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Cabaleiro Joe	Sep/Oct 2021 Pg. 358-362
Standing Together Fixing the Drug Quality and Security Act Miller David G	Mar/Apr 2015 Pg. 104-106
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing Allen Loyd V Jr	Mar/Apr 2018 Pg. 92
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Allowing Compounding Pharmacies to Address Drug Shortages Broughel James	Mar/Apr 2022 Pg. 100-109
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Blankenship Cynthia E	Sep/Oct 2014 Pg. 379-380
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr	Nov/Dec 2003 Pg. 449-450
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
PreScription: Comments on the FDA Guidance "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry" Allen Loyd V Jr	Mar/Apr 2022 Pg. 92
U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Miller David G	Jan/Feb 2014 Pg. 35-36
PreScription: Compounding Pharmacy Issues for 2017 Allen Loyd V Jr	Jan/Feb 2017 Pg. 4
PreScription: CompoundingToday.com and Sources of Compounding Chemicals Allen Loyd V Jr	Jan/Feb 2005 Pg. 2
Applying Quality of Design Concepts to Pharmacy Compounding Timko Robert J	Nov/Dec 2015 Pg. 453-463
The Evolution of 21 CFR Parts 210 & 211 for Drug Compounders: An Unspoken Opportunity for Pharmacists Parks Kenneth Chase, Bernard Brian, Cogdill Christopher Blake	Sep/Oct 2015 Pg. 377-380
PreScription: Déjà Vu All Over Again Allen Loyd V Jr	May/Jun 2014 Pg. 180
Return to Top